The pharmaceutical outsourcing firm has acquired space to expand a number of key departments in Tredegar, South Wales
Pharmaceutical outsourcing specialist PCI Pharma Services is to expand its facility in Tredegar, South Wales, continuing a policy of regular investment at the site.
The firm has acquired a further 26,500 ft2 (about 2,500 m2) at the Tafarnaubach Industrial Estate in Tredegar to house a number of key departments to support continued business growth, including offices and laboratories.
The next phase of the investment will help deliver a centre of excellence for analytical services.
The Tredegar site was previously expanded in 2013 with the opening of a dedicated Contained Manufacturing Facility (CMF) to enable the specialist processing of highly potent molecules into tablets and capsules using contained technology.
In 2014, PCI acquired Penn Pharma, adding drug manufacturing to its portfolio of services and the firm has continued its substantial investment in this specialisation. In a further investment programme, PCI increased the capacity of Penn's large-scale commercial manufacturing capabilities by adding a single pot granulation process.
In 2015, additional granulation capabilities were added in the form of roller compaction technology providing a granulation technique for products sensitive to heat and moisture. The Gerteis MiniPactor is also fully contained technology, further complimenting the site specialisation for the development and manufacturing of highly potent molecules. This year has seen continued investment in the form of contained Xcelodose technology, providing a cost- and time-effective option for first-in-man studies.
Norman Barras, Managing Director, PCI Pharma Services Tredegar, said: 'I am delighted that we are continuing to grow and expand as a site. This additional footprint will ensure that we are even more able to meet the growth demands of our business and deliver excellence to each and every customer.'
Barras continued: 'The site has benefited from significant investment over the last five or so years, delivering a centre of excellence for manufacturing and uniquely positioning PCI Pharma Services within the global marketplace. This next phase of investment will help deliver a centre of excellence for analytical services.'
Ken Richardson, Global Vice President, Engineering, PCI Pharma Services added: 'With world-leading capabilities for the development and manufacturing of pharmaceutical products, this investment in and expansion of the Tredegar site will ensure that we continue to provide a truly integrated full-service solution to our clients.'